Park Avenue Securities LLC Purchases 208,092 Shares of Kenvue Inc. (NYSE:KVUE)

Park Avenue Securities LLC lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 860.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 232,282 shares of the company’s stock after buying an additional 208,092 shares during the period. Park Avenue Securities LLC’s holdings in Kenvue were worth $4,959,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Leo Wealth LLC boosted its stake in Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares in the last quarter. Alerus Financial NA boosted its stake in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its holdings in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares during the last quarter. Wolff Wiese Magana LLC increased its position in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. Finally, Marathon Capital Management lifted its stake in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after purchasing an additional 514 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on KVUE shares. Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, UBS Group dropped their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.27.

Kenvue Trading Up 1.7 %

NYSE:KVUE opened at $21.21 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm’s fifty day moving average is $22.47 and its 200-day moving average is $21.64. The firm has a market cap of $40.66 billion, a P/E ratio of 38.56, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the prior year, the firm posted $0.31 earnings per share. The business’s quarterly revenue was down .4% compared to the same quarter last year. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.